-
1Academic Journal
Neuromyelitis optica spectrum disorders in children ; Заболевания спектра оптиконевромиелита у детей
Authors: N. F. Akhmetgaleeva, T. O. Simaniv, E. M. Yausheva, Yа. A. Saitova, O. V. Lyutov, M. A. Kutlubaev, K. Z. Bakhtiyarova, Н. Ф. Ахметгалеева, Т. О. Симанив, Э. М. Яушева, Я. А. Саитова, О. В. Лютов, М. А. Кутлубаев, К. З. Бахтиярова
Contributors: The investigation has not been sponsored, Исследование не имело спонсорской поддержки
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16 (2024): (Suppl. 2); 65-73 ; Неврология, нейропсихиатрия, психосоматика; Vol 16 (2024): (Suppl. 2); 65-73 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-0
Subject Terms: лечение, neuromyelitis optica spectrum diseases, aquaporin-4, paediatric patients, differential diagnosis, treatment, заболевания спектра оптиконевромиелита, аквапорин-4, дети, дифференциальная диагностика
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2318/1692; Jarius S, Aktas O, Ayzenberg I, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-68. doi:10.1007/s00415-023-11634-0. Epub 2023 Apr 6.; Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to WorkUp and Diagnosis. Front Pediatr. 2020 Jun 25;8:339. doi:10.3389/fped.2020.00339. Erratum in: Front Pediatr. 2021 Feb 15;8:642203. doi:10.3389/fped.2020.642203; Хайбуллин ТН, Кириллова ЕВ, Бикбаев РМ и др. Клинико-эпидемиологические характеристики рассеянного склероза и оптиконейромиелита в Центральной Азии. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(2-2):12-7. doi:10.17116/jnevro20191192212; Papp V, Magyari M, Aktas O, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2021 Jan 12;96(2):59-77. doi:10.1212/WNL.0000000000011153. Epub 2020 Dec 11.; Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi:10.3389/fneur.2020.00501; Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016 Jan 19;86(3):245-52. doi:10.1212/WNL.0000000000002283. Epub 2015 Dec 18.; Fragoso YD, Ferreira ML, Oliveira EM, et al. Neuromyelitis optica with onset in childhood and adolescence. Pediatr Neurol. 2014 Jan;50(1):66-8. doi:10.1016/j.pediatrneurol.2013.07.003. Epub 2013 Oct 13.; Стародубов ВИ, Зеленова ОВ, Абрамов СИ и др. Первое обсервационное эпидемиологическое исследование по определению заболеваемости и распространенности заболеваний спектра оптиконевромиелита (оптиконевромиелит, болезнь Девика) на территории Российской Федерации. Современные проблемы здравоохранения и медицинской статистики. 2021;(1):130-41. doi:10.24411/2312-2935-2021-00007; Луцик ВН, Котов АС, Борисова МН и др. Оптикомиелит Девика у ребенка. Неврологический журнал. 2017;22 (4):205-10. doi:10.18821/1560-9545-2017-22-4-205-210; Котов АС, Токарева ЮВ, Луцик ВН и др. Расстройство изспектра оптиконевромиелита в детском возрасте (клинический случай). Русский журнал детской неврологии. 2017;(4):56-62. doi:10.17650/2073-8803-2017-12-4-56-62; Токарева ЮВ, Котов АС, Пантелеева МВ и др. Расстройства из спектра оптиконевромиелита у пациентов детского возраста. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):60-4. doi:10.14412/2074-2711-2018-1-60-64; Abe Y, Yasui M. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System. Biomolecules. 2022 Apr 17;12(4):591. doi:10.3390/biom12040591; Зайцева ПА, Бойко АН. Заболевания спектра оптиконевромиелита: от патогенеза к таргетной терапии. Неврология, нейропсихиатрия, психосоматика. 2023;15(Прил. 1):49-57. doi:10.14412/2074-2711-2023-1S-49-57; Trebst C, Jarius S, Berthele A, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014 Jan;261(1):1-16. doi:10.1007/s00415-013-7169-7. Epub 2013 Nov 23.; Cazzaniga J, Jara Silva CE, Quinonez J, et al. Neuromyelitis Optica Spectrum Disorder. Cureus. 2023 Nov 2;15(11):e48168. doi:10.7759/cureus.48168; Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023 Sep 28;14:1255533. doi:10.3389/fimmu.2023.1255533; Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 20;7(5):e841. doi:10.1212/NXI.0000000000000841; Симанив ТО, Бахтиярова КЗ, Белова АН и др. Заболевания спектра оптиконевромиелита (ЗСОНМ) – диагностические критерии и подходы к терапии. Неврология, нейропсихиатрия, психосоматика. 2023;15(Прил. 1):71-5. doi:10.14412/2074-2711-2023-1S-71-75; Yan Y, Li Y, Fu Y, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016 Dec;59(12):1270-81. doi:10.1007/s11427-015-4997-y. Epub 2016 Feb 26.; Bruijstens AL, Lechner C, Flet-Berliac L, et al. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13. doi:10.1016/j.ejpn.2020.10.006. Epub 2020 Nov 4.; Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi:10.1212/WNL.0000000000001729. Epub 2015 Jun 19.; Белова АН, Бойко АН, Белова ЕМ. Диагностические критерии оптикомиелит- ассоциированных расстройств. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2016;116(2-2):32-40. doi:10.17116/jnevro20161162232-40; Baghbanian SM, Asgari N, Sahraian MA, Moghadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018 May 15;388:222-31. doi:10.1016/j.jns.2018.02.028. Epub 2018 Feb 19.; Paolilo RB, Hacohen Y, Yazbeck E, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 30;7(5):e837. doi:10.1212/NXI.0000000000000837; Camera V, Messina S, Elhadd KT, et al. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):101-11. doi:10.1136/jnnp-2021-327206. Epub 2021 Sep 28.; Hacohen Y, Messina S, Gan HW, et al. Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. Mult Scler. 2018 Apr;24(5):679-84. doi:10.1177/1352458517726593. Epub 2017 Aug 14.; Kim HJ, Paul F, Lana-Peixoto MA, et al; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. doi:10.1212/WNL.0000000000001367. Epub 2015 Feb 18.; Bourre B, Zephir H, Ongagna JC, et al. Long-term follow-up of acute partial transverse; Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014 May;20(6):695-704. doi:10.1177/1352458513506953. Epub 2013 Sep 26.; Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72. doi:10.1136/jnnp-2014-308346. Epub 2014 Aug 13.; Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485-9. doi:10.1212/01.wnl.0000216139.44259.74; Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013 Apr 2;80(14):1330-7. doi:10.1212/WNL.0b013e3182887957. Epub 2013 Mar 13.; Mader S, Obholzer B, Reindl M. Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights. InTech. 2011. doi:10.5772/20517; Yin HX, Wang YJ, Liu MG, et al. Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants. Ann Neurol. 2023 Jun;93(6):1069-81. doi:10.1002/ana.26623. Epub 2023 Mar 13.; Poisson K, Moeller K, Fisher KS. Pediatric Neuromyelitis Optica Spectrum Disorder. Semin Pediatr Neurol. 2023 Jul;46:101051. doi:10.1016/j.spen.2023.101051. Epub 2023 Apr 30.; Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019 Jan;27:350-63. doi:10.1016/j.msard.2018.11.008. Epub 2018 Nov 16.; Mealy MA, Kozachik SL, Levy M. Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Manag Nurs. 2019 Dec;20(6):580-91. doi:10.1016/j.pmn.2019.03.003. Epub 2019 May 15.; Ferilli MAN, Paparella R, Morandini I, et al. Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life (Basel). 2021 Dec 23;12(1):19. doi:10.3390/life12010019 A systematic review and meta-analysis. J Neuroimmunol. 2020 Nov 20;350:577449. doi:10.1016/j.jneuroim.2020.577449. Epub ahead of print.; Li Z, Wan L, Liu X, et al. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. Front Immunol. 2023 Jan 5;13:1113406. doi:10.3389/fimmu.2022.1113406; Zhou Y, Zhong X, Shu Y, et al. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019 Feb;28:213-20. doi:10.1016/j.msard.2018.12.038. Epub 2019 Jan 3.; Paolilo RB, da Paz JA, Apostolos-Pereira SL, et al. Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort. Mult Scler Relat Disord. 2021 Nov;56:103252. doi:10.1016/j.msard.2021.103252. Epub 2021 Sep 10.; Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012 Oct;18(10):1480-3. doi:10.1177/1352458512439439. Epub 2012 Feb 21.; Ayzenberg I, Schöllhammer J, Hoepner R, et al; Neuromyelitis Optica Study Group. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retro- spective study. J Neurol. 2016 Mar;263(3):575-82. doi:10.1007/s00415-015-7991-1. Epub 2016 Jan 25.; Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 Jan;18(1):113-5. doi:10.1177/1352458511431973. Epub 2011 Dec 6.; Bonnan M, Berthelot E, Cabre P. Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation. Mult Scler Relat Disord. 2021 Jul;52:102975. doi:10.1016/j.msard.2021.102975. Epub 2021 Apr 24.; Gahlen A, Trampe AK, Haupeltshofer S, et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi:10.1212/NXI.0000000000000363; Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016 Jan;263(1):25-9. doi:10.1007/s00415-015-7925-y; Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. myelitis. Arch Neurol. 2012 Mar;69(3):357-62. doi:10.1001/archneurol.2011.949. Erratum in: Arch Neurol. 2012 Jun;69(6):789.; Yu HH, Qin C, Zhang SQ, et al. Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: Mult Scler. 2017 Aug;23(9):1297-300. doi:10.1177/1352458517694086. Epub 2017 Apr 10.; Прахова ЛН, Краснов ВС, Касаткин ДС и др. Локальный опыт применения препарата сатрализумаб, подавляющего путь IL-6, для терапии заболеваний спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2022;122(7-2):68-72. doi:10.17116/jnevro202212207268; Heo YA. Satralizumab: First Approval. Drugs. 2020 Sep;80(14):1477-82. doi:10.1007/s40265-020-01380-2. Erratum in: Drugs. 2020 Sep;80(14):1483. doi:10.1007/s40265-020-01391-z; Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi:10.1056/NEJMoa1901747; Li X, Wu W, Zeng Y, et al. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report. Front Immunol. 2023 Oct 17;14:1257955. doi:10.3389/fimmu.2023.1257955; Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi:10.1056/NEJMoa1900866. Epub 2019 May 3.; Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 Jun;93(6):1053-68. doi:10.1002/ana.26626. Epub 2023 Apr 5.; Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика. 2017;16(1):51-4.; Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8;83(2):142-50. doi:10.1212/WNL.0000000000000570. Epub 2014 Jun 11.; Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e188. doi:10.1212/NXI.0000000000000188; Deya-Martinez A, Gordon Y, Molina-Anguita C, et al. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm. 2020 May 6;7(4):e724. doi:10.1212/NXI.0000000000000724; Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019 Aug;33:22-32. doi:10.1016/j.msard.2019.05.011. Epub 2019 May 22.
-
2
-
3Academic Journal
Authors: N. L. Sheremet, D. D. Eliseeva, V. V. Bryukhov, N. A. Andreeva, N. V. Zhorzholadze, Yu. K. Murakhovskaya, A. K. Kalashnikova, M. N. Zakharova, Н. Л. Шеремет, Д. Д. Елисеева, В. В. Брюхов, Н. А. Андреева, Н. В. Жоржоладзе, Ю. К. Мураховская, А. К. Калашникова, М. Н. Захарова
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 15 (2023): (Suppl. 1); 35-42 ; Неврология, нейропсихиатрия, психосоматика; Vol 15 (2023): (Suppl. 1); 35-42 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-0
Subject Terms: магнитно-резонансная томография, demyelination, multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody- associated disease, optical coherence tomography, magnetic resonance imaging, демиелинизация, рассеянный склероз, заболевания спектра оптиконевромиелита, заболевания центральной нервной системы, ассоциированные с антителами к миелинолигодендроцитарному гликопротеину, оптическая когерентная томография
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2077/1573; Bennett J, Costello F, Chen J, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023 Jan;22(1):89-100. doi:10.1016/S1474-4422(22)00187-9; Jenkins TM, Toosy AT. Optic neuritis: the eye as a window to the brain. Curr Opin Neurol. 2017 Feb;30(1):61-6. doi:10.1097/WCO.0000000000000414; Gaier ED, Boudreault K, Rizzo JF 3rd, et al. Atypical Optic Neuritis. Curr Neurol Neurosci Rep. 2015 Dec;15(12):76. doi:10.1007/s11910-015-0598-1; McGinley P, Goldschmidt, C, Rae-Grant A. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021 Feb 23;325(8):765-79. doi:10.1001/jama.2020.26858; Zhang Y, Qiu W, Guan H, et al. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol. 2022 Mar 2;13:844155. doi:10.3389/fneur.2022.844155; Foo R, Yau C, Singhal S, et al. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia Pac J Ophthalmol (Phila). 2022 Mar-Apr 01;11(2):184-95. doi:10.1097/APO.0000000000000513; Lennon V, Wingerchuk D, Kryzer T, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17;364(9451):2106-12. doi:10.1016/S0140-6736(04)17551-X; Lennon V, Kryzer T, Pittock S, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7. doi:10.1084/jem.20050304; Häusser-Kinzel S, Weber M. The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Front Immunol. 2019 Feb 8;10:201. doi:10.3389/fimmu.2019.00201; Jacob A, McKeon I, Nakashima, D, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):922-30. doi:10.1136/jnnp-2012-302310; Wingerchuk D, Banwell B, Bennett J, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi:10.1212/WNL.0000000000001729; Hamid S, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017 Oct;264(10):2088-94. doi:10.1007/s00415-017-8596-7; Flanagan B. Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Contin Lifelong Learn Neurol. 2019;25:815-44. doi:10.1212/CON.0000000000000742; Pröbstel A, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46. doi:10.1186/s12974-015-0256-1; Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb 11;82(6):474-81. doi:10.1212/WNL.0000000000000101. Epub 2014 Jan 10.; Peschl P, Schanda K, Zeka B, et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. 2017 Oct 25;14(1):208. doi:10.1186/s12974-017-0984-5; Waters P, Fadda G, Woodhall M, et al. Canadian Pediatric Demyelinating Disease Network. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020 Jan 1;77(1):82-93. doi:10.1001/jamaneurol.2019.2940; Jarius S, Metz I, Konig F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016 Oct;22(12):1541-9. doi:10.1177/1352458515622986; Sechi E, Cacciaguerra L, Chen J, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022 Jun 17;13:885218. doi:10.3389/fneur.2022.885218; Wildemann B, Horstmann S, Korporal-Kuhnke M, et al. Aquaporin-4-und Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Optikusneuritis: Diagnose und Therapie [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment]. Klin Monbl Augenheilkd. 2020 Nov;237(11):1290-305. doi:10.1055/a-1219-7907 (In Germ.)].; Tanaka S, Hashimoto B, Izaki S, et al. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody- positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Mult Scler Relat Disord. 2020 Jun;41:102005. doi:10.1016/j.msard.2020.102005; Akaishi T, Takahashi T, Misu T, et al. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2021 Jul 6;97(1):e1-e12. doi:10.1212/WNL.0000000000012175; Beck R, Cleary P, Backlund J, et al. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994 Nov;101(11):1771-8. doi:10.1016/s0161-6420(94)31103-1; Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology. 2009 Sep 22;73(12):949-53. doi:10.1212/WNL.0b013e3181b879be; Roesner S, Appel R, Gbadamosi J, et al. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012 Aug;126(2):103-8. doi:10.1111/j.1600-0404.2011.01612.x. Epub 2011 Nov 2.; Banwell B, Bennett J, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-82. doi:10.1016/S1474-4422(22)00431-8; Jurynczyk M, Messina S, Woodhall R, et al. Clinical presentation and prognosis in MOGantibody disease: a UK study. Brain. 2017 Dec 1;140(12):3128-38. doi:10.1093/brain/awx276. Erratum in: Brain. 2018 Apr 1;141(4):e31.; Kurane K, Monden Y, Tanaka D, et al. MOG-Ab titer-guided approach for steroid tapering to prevent relapse in children with mog antibody-associated adem diseases: A case report. Mult Scler Relat Disord. 2020 Oct;45:102320. doi:10.1016/j.msard.2020.102320; Deneve M, Biotti D, Patsoura S, et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol. 2019 Sep;46(5):312-8. doi:10.1016/j.neurad.2019.06.001. Epub 2019 Jun 20.; Salama S, Khan M, Shanechi A, et al. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020 Dec;26(14):1854-65. doi:10.1177/1352458519893093. Epub 2020 Jan 15.; Havla J, Pakeerathan T, Schwake C, et al. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation. 2021 May 29;18(1):121. doi:10.1186/s12974-021-02160-9; Dutra B, da Rocha A, Nunes R, et al. Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. Radiographics. 2018 Jan-Feb;38(1):169-93. doi:10.1148/rg.2018170141; Carandini T, Sacchi L, Bovis F, et al. Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021 Sep;54:103118. doi:10.1016/j.msard.2021.103118; Filippatou A, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020 Oct 8;11:540156. doi:10.3389/fneur.2020.540156; Sotirchos E, Filippatou A, Fitzgerald K, et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler. 2020 Oct;26(11):1360-71. doi:10.1177/1352458519864928; Akaishi T, Takahashi T, Fujihara K, et al. Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2021 May;268(5):1938-44. doi:10.1007/s00415-020-10377-6; Wang X, Shi Z, Zhao Z, et al. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. Front Immunol. 2022 Sep29;13:959469. doi:10.3389/fimmu.2022.959469
-
4Academic Journal
Authors: V. E. Avdeeva, A. S. Kotov, В. Е. Авдеева, А. С. Котов
Source: Russian Journal of Child Neurology; Том 16, № 3 (2021); 21-33 ; Русский журнал детской неврологии; Том 16, № 3 (2021); 21-33 ; 2412-9178 ; 2073-8803 ; 10.17650/2073-8803-2021-16-3
Subject Terms: острый рассеянный энцефаломиелит, myelin-oligodendrocytic glycoprotein, AQP-4, aquaporin 4, neuromyelitis optic spectrum diseases, optic neuritis, myelitis, acute disseminated encephalomyelitis, миелин-олигодендроцитарный гликопротеин, аквапорин 4, заболевания спектра оптиконевромиелита, оптический неврит, миелит
File Description: application/pdf
Relation: https://rjdn.abvpress.ru/jour/article/view/371/251; De Seze J. MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease? Brain 2017;140(12):3072-5. DOI:10.1093/brain/awx292.; Dos Passos G.R., Oliveira L.M., da Costa B.K. et al. MOG-IgG-asso-ciated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 2018;9:217. DOI:10.3389/fneur.2018.00217.; Fabriek B.O., Zwemmer J.N., Teunissen C.E. et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 2005;161(1-2):190-4. DOI:10.1016/j.jneuroim.2004.12.018.; Jarius S., Paul F., Aktas O. et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15,134. DOI:10.1186/s12974-018-1144-2.; Jurynczyk M., Messina S., Woodhall M.R. et al. Clinical presentation and prognosis in MOG-antibody disease: A UK study. Brain 2017;140(12):3128-38. DOI:10.1093/brain/awx276.; Narayan R., Simpson A., Fritsche K. et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018;25:66-72. DOI:10.1016/j.msard.2018.07.025.; Reindl M., Jarius S., Rostasy K., Berger T. Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol 2017;30(3):295-301. DOI:10.1097/WCO.0000000000000446.; Reindl M., Schanda K., Woodhall M. et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020;7(2):e674. DOI:10.1212/NXI.0000000000000674.; Sato D.K., Callegaro D., Lana-Peixoto M.A. et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82(6):474-81. DOI:10.1212/WNL.0000000000000101.; Weber M.S., Derfuss T., Bruck W Anti-myelin oligodendrocyte glycoprotein antibody-associated central nervous system demyelination - a novel disease entity? JAMA Neurol 2018;75(8):909-10. DOI:10.1001/jamaneurol.2018.1055.; Weber M.S., Derfuss T., Metz I., Bruck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord 2018;11:1756286418762083. DOI:10.1177/1756286418762083.; Weinshenker B.G., Wingerchuk D.M. Neuromyelitis spectrum disorders. Mayo Clin Proc 2017;92(4):663-79. DOI:10.1016/j.mayocp.2016.12.014.; Wingerchuk D.M., Banwell B., Bennett J.L. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-89. DOI:10.1212/WNL.0000000000001729.; https://rjdn.abvpress.ru/jour/article/view/371
-
5Academic Journal
Authors: S. V. Kotov, E. S. Novikova, A. S. Kotov, С. В. Котов, Е. С. Новикова, А. С. Котов
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 4 (2021); 18-24 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 4 (2021); 18-24 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-4
Subject Terms: ритуксимаб, neuromyelitis optica spectrum disorders, AQP4-IgG, MOG-IgG, rituximab, заболевания спектра оптиконевромиелита
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1620/1272; https://nnp.ima-press.net/nnp/article/view/1620/1287; Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013 Jan 15;10:8. doi:10.1186/1742-2094-10-8; Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014 Jan;24(1):83-97. doi:10.1111/bpa.12099; Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. doi:10.1212/WNL.0000000000001729; Котов АС. Синдром anti-MOG: описание двух случаев. Неврология, нейропсихиатрия, психосоматика. 2019;11(1):84-8. doi:10.14412/2074-2711-2019-1-84-88; Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276-83. doi:10.1001/jamaneurol.2013.5857; Jarius S, Ruprecht K, Kleiter I, et al; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. doi:10.1186/s12974-016-0718-0; Pandit L, Sato DK, Mustafa S, et al. Serological markers associated with neuromyelitis optica spectrum disorders in South India. Ann Indian Acad Neurol. 2016 Oct-Dec;19(4):505-9. doi:10.4103/09722327.192389; Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-81. doi:10.1212/WNL.0000000000000101; Cross H, Sabiq F, Ackermans N, et al. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort. Front Neurol. 2021 Jan 12;11:525933. doi:10.3389/fneur.2020.525933. eCollection 2020.; Токарева ЮВ, Котов АС, Пантелеева МВ, Бунак МС. Расстройства из спектра оптиконевромиелита у пациентов детского возраста. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):60-4. doi:10.14412/2074-2711-2018-1-60-64; Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019 Jun;32(3):385-94. doi:10.1097/WCO.0000000000000694; Borisow N, Mori M, Kuwabara S, et al. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018 Oct 23;9:888. doi:10.3389/fneur.2018.00888. eCollection 2018.; Симанив ТО, Васильев АВ, Аскарова ЛШ, Захарова МН. Оптиконейро-миелит и заболевания спектра оптиконей-ромиелита. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019;119(10-2):35-48. doi:10.17116/jnevro20191191035; Kimbrough DJ, Fujihara K, Jacob A, et al; GJCF-CC&BR. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord. 2012 Oct;1(4):180-7. doi:10.1016/j.msard.2012.06.002; Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):927-36. doi:10.1136/jnnp-2018-317969. Epub 2018 Jun 6.; Axtell RC, Raman C, Steinman L. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol. 2013 Apr;44(2):114-20. doi:10.1007/s12016-011-8296-5; Kleiter I, Gahlen A, Borisow N, et al; Neuromyelitis Optica Study Group. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016 Feb;79(2):206-16. doi:10.1002/ana.24554. Epub 2015 Nov 26.; Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler. 2016 Feb;22(2):185-92. doi:10.1177/1352458515581438. Epub 2015 Apr 28.; Ellwardt E, Ellwardt L, Bittner S, Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm. 2018 Apr 25;5(4):e463. doi:10.1212/NXI.0000000000000463. eCollection 2018 Jul.; Evangelopoulos ME, Andreadou E, Koutsis G, et al. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. J Neurol Sci. 2017 Jan 15;372:92-6. doi:10.1016/j.jns.2016.11.016. Epub 2016 Nov 10.; Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-12. doi:10.1016/S1474-4422(20)30078-8; Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi:10.1056/NEJMoa1900866. Epub 2019 May 3.; Cree BAC, Bennett JL, Kim HJ, et al; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct ;394(10206):1352-63. doi:10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.; Jurynczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016 Jan;263(1):140-9. doi:10.1007/s00415-015-7952-8. Epub 2015 Nov 3.; Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005 Apr 12;64(7):1270-2. doi:10.1212/01.WNL.0000159399.81861.D5; Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol. 2016 Nov 1;73(11):1342-8. doi:10.1001/jamaneurol.2016.1637; Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019 Mar 6;19(1):36. doi:10.1186/s12883-019-1261-2; Ciron J, Audoin B, Bourre B, et al; NOMADMUS group, under the aegis of OFSEP, SFSEP. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018 Apr;174(4):255-64. doi:10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30.; Schmetzer O, Lakin E, Roediger B, et al. Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Front Neurol. 2021;12:635419. doi:10.3389/fneur.2021.635419
-
6Report
Subject Terms: антитела к аквапорину-4, Ярославская область, эпидемиология, aquaporin-4 immunoglobulin G antibodies, демиелинизирующие заболевания, demyelinating diseases, neuromyelitis optica, заболевания спектра оптиконевромиелита, epidemiology, neuromyelitis optica spectrum disorders, Yaroslavl region, оптиконевромиелит, 3. Good health
-
7Report
Subject Terms: антитела к миелин-олигодендроцитарному гликопротеину, заболевания спектра оптиконевромиелита (ЗСОНМ), антитела к аквапорину-4, эпидемиология, демиелинизирующие заболевания, multiple sclerosis, оптиконевромиелит, neuromyelitis optica (NMO), 3. Good health, myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG), aquaporin-4 immunoglobulin G antibodies (AQP4-IgG), neuromyelitis optica spectrum disorders (NMOSD), demyelinating diseases, рассеянный склероз (РС), epidemiology